Curt Herberts is signing on at synthetic biology startup Senti Biosciences as its new chief financial officer and chief business officer. First up on the docket? Figuring out the company’s partnering strategy and how to blend it with its corporate strategy, he says.
Herberts joins Senti from genome-editing company Sangamo Therapeutics, where he also served as chief business officer. At Sangamo, he spearheaded a number of deals, including a collaboration around its zinc finger protein technology with Shire, a blood disorder-focused pact with Biogen potentially worth $320 million, a pair of partnerships with Pfizer and a $3 billion off-the-shelf CAR-T deal that would give Gilead access to its zinc finger nuclease tech.
Senti’s work centers on synthetic gene circuits that make cell and gene therapies “smarter”—that is, making them able to “respond dynamically” to the disease conditions they encounter. The company also aims to make such therapies controllable in vivo once they are delivered.
“We are using that cell circuitry to improve efficacy, safety and tolerability,” he told FierceBiotech. “[It can] expand the potential for where cell and gene therapies can go, [such as] beyond liquid cancers and into solid tumors.”
Cell therapies, such as CAR-T, have seen limited success in solid tumors due to selectivity issues: “It’s hard to find the one magic bullet marker on a cancer cell that is not found in any other cell type. The challenge is how to find cancer cells and kill them without killing anything else,” said Senti co-founder Wilson Wong in a previous interview. Senti is working with Wong and his team to translate what they call the “Swiss army knife” of CAR-T into clinical development.
In his new role, Herberts will guide Senti as it builds its in-house pipeline while also partnering on further applications of its synthetic biology platform, Senti said in a statement.
“First is the age-old question for a technology platform company: where are we going to invest in the platform? Where are we going to invest in the therapeutics?” he said. As for blending Senti’s corporate strategy with its external partner strategy, he’s working on how to decide which assets to keep and which to partner on. And “how do you partner” is a key question too.
“It’s not just binary,” he said.
“As Senti continues to advance several programs towards the clinic, Curt’s experience will prove invaluable in building a long-term fully integrated cell and gene therapy company developing adaptive therapies for patients in need,” said Senti CEO Tim Lu in the statement.
By Amirah Al Idrus
Source: Fierce Biotech
Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.
Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.
The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).